UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2006
PHARMAFRONTIERS CORP.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Texas 000-25513 76-0333165
- ----------------------- ------------------------ --------------------
(State of organization) (Commission File Number) (IRS Employer
Identification No.)
2635 N. Crescent Ridge Drive
The Woodlands, Texas 77381
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's Telephone Number, including area code: (281) 272-9331
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a- 12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Election of Directors
On June 15, 2006, the board of directors appointed Michael Richman to the
Board of Directors. Mr. Richman was also appointed to the board's audit,
compensation and nominating committees.
Michael S. Richman, MSBA., is executive vice president and chief operating
officer of MacroGenics, Inc. located in Rockville, MD. He joined the firm in
2002 with over twenty years experience in corporate business development within
the biotechnology industry. Before joining MacroGenics Inc, he was senior vice
president, corporate development administration at MedImmune, Inc. from 1996 to
2002. From 1985 to 1996, Mr. Richman served in various senior positions at
Chiron Corporation, a public biotechnology company, with his last position being
director of corporate business development. His previous positions include:
manager of business development, from 1990 to 1992 and manager of intellectual
property from 1988 to 1990. Mr. Richman also serves on the board of directors of
Cougar Biotechnology, Inc., a publicly traded biotechnology company.
Mr. Richman has not been involved with a related transaction or
relationship as defined by Item 404(a) of Regulation S-B with the Company.
Item 9.01 Financial Statements and Exhibit
(c) Exhibits
The following exhibits are to be filed as part of this 8-K:
Exhibit No. Identification of Exhibit
----------- -------------------------
99.1 Press Release dated June 16, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMAFRONTIERS CORP.
By: /s/ David McWilliams
-----------------------------------------
David McWilliams, Chief Executive Officer
DATE: June 16, 2006
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release dated June 16, 2006